Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Universal Human Papillomavirus Vaccination and its Impact on the Southern Italian Region

Author(s): Marcello Guido*, Annarita Bruno, Luigi Tagliaferro, Valerio Aprile, Andrea Tinelli, Alberto Fedele, Giambattista Lobreglio, Paola Menegazzi, Giancarlo Pasanisi, Vittorio Tassi, Bruno Forcina, Francesca Fortunato, Laura Isabella Lupo and Antonella Zizza

Volume 26, Issue 3, 2020

Page: [343 - 357] Pages: 15

DOI: 10.2174/1381612826666200212115840

Price: $65

Abstract

HPV is still the most common sexually transmitted infection, leading to the onset of many disorders while causing an increase in direct and indirect health costs. High Risk (HR) HPV is the primary cause of invasive cervical cancer and contributes significantly to the development of anogenital and oropharyngeal cancers. The introduction of universal HPV vaccination has led to a significant reduction in vaccine-targeted HPV infections, cross-protective genotypes, precancerous lesions and anogenital warts. Despite the several limitations of HPV vaccination programs, including vaccine type specificity, different schedules, target age-groups and poor communication, the impact has become increasingly evident, especially in countries with high vaccine uptake. We carried out a review of the most recent literature to evaluate the effects of HPV vaccination on vaccinetargeted HPV genotypes and to assess the level of cross-protection provided against non-vaccine HPV types. Subsequently, to assess the rates of HPV infection in a southeast Italian region, we performed an epidemiological investigation on the impact of vaccination on genotypes and on the prevalence and distribution of HPV infection during the twelve-year period 2006-2017 in the Local Health Unit (LHU) of Lecce. The vaccination coverage of about 70% among girls in the LHU led to an initial reduction in vaccine-targeted HPV types and cross-protective genotypes. However, the results on this population should be interpreted cautiously because the period since the start of vaccination is too short and the coverage rate is not yet optimal to evaluate the efficacy of vaccination in lowering the prevalence of non-vaccine HR HPV types in the vaccinated cohort and in older subjects. Nevertheless, it is expected that direct effects will increase further and that herd immunity will begin to emerge as vaccination coverage increases.

Keywords: HPV, vaccination, cervical cancer, anal cancers, HPV genotype test, sexual transmitted disease.

« Previous Next »
[1]
Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016; 2: 16086.
[http://dx.doi.org/10.1038/nrdp.2016.86] [PMID: 27905473]
[2]
International Human Papillomavirus Reference Center. Human Reference clones Available at:. http://www.hpvcenter.se
[3]
Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401(1): 70-9.
[http://dx.doi.org/10.1016/j.virol.2010.02.002] [PMID: 20206957]
[4]
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100(Pt B): 1-441.
[PMID: 23189750]
[5]
Muñoz N, Bosch FX, de Sanjosé S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-27.
[http://dx.doi.org/10.1056/NEJMoa021641] [PMID: 12571259]
[6]
Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014; 23(10): 1997-2008.
[http://dx.doi.org/10.1158/1055-9965.EPI-14-0410] [PMID: 25274978]
[7]
Alemany L, Saunier M, Alvarado-Cabrero I, et al. HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136(1): 98-107.
[http://dx.doi.org/10.1002/ijc.28963] [PMID: 24817381]
[8]
de Sanjosé S, Alemany L, Ordi J, et al. HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49(16): 3450-61.
[http://dx.doi.org/10.1016/j.ejca.2013.06.033] [PMID: 23886586]
[9]
de Sanjosé S, Quint WG, Alemany L, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11(11): 1048-56.
[http://dx.doi.org/10.1016/S1470-2045(10)70230-8] [PMID: 20952254]
[10]
de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7(7): 453-9.
[http://dx.doi.org/10.1016/S1473-3099(07)70158-5] [PMID: 17597569]
[11]
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202(12): 1789-99.
[http://dx.doi.org/10.1086/657321] [PMID: 21067372]
[12]
Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199(6): 805-14.
[http://dx.doi.org/10.1086/597071] [PMID: 19199546]
[13]
Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191(5): 731-8.
[http://dx.doi.org/10.1086/427557] [PMID: 15688287]
[14]
Herrero R, González P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015; 16(5): e206-16.
[http://dx.doi.org/10.1016/S1470-2045(14)70481-4] [PMID: 25943065]
[15]
World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec 2017; 92(19): 241-68.
[PMID: 28530369]
[16]
Tinelli A, Guido M, Zizza A, et al. The mRNA-HPV test utilization in the follow up of HPV related cervical lesions. Curr Pharm Des 2013; 19(8): 1458-65.
[PMID: 23016779]
[17]
Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006; 194(8): 1044-57.
[http://dx.doi.org/10.1086/507432] [PMID: 16991079]
[18]
World Health Organization (WHO). Human papillomavirus (HPV) and cervical cancer. Available at:. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
[19]
Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). human papillomavirus and related diseases in Europe. Summary Report 2019 June 171-99.Available at:. https://hpvcentre.net/statistics/ reports/ XEX.pdf?t=1567845626447
[20]
Associazione Italiana di Oncologia Medica (AIOM). I numeri del cancro in Italia 2018. Intermedia Editore, Brescia 2018; 244-6.Available at:. https://www.aiom.it/ wpcontent/ uploads/ 2018/ 10/2018_NumeriCancro-operatori.pdf
[21]
European Medicines Agency (EMA). Gardasil. Product information.. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp
[22]
European Medicines Agency (EMA). Cervarix. Product information.. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/hman/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124
[23]
Cappelli MG, Fortunato F, Tafuri S, et al. Cervical cancer prevention: an Italian scenario between organised screening and human papillomaviruses vaccination. Eur J Cancer Care (Engl) 2018; 27(5) e12905
[http://dx.doi.org/10.1111/ecc.12905] [PMID: 30178893]
[24]
Ministero della Salute. Intervento del Ministro della Salute. Conferenza stampa: presentazione campagna vaccinale contro l’HPV. 22 febbraio 2008 Available at:. http://www.ministerosalute.it/ speciali/documenti/vaccinazioni/HPV_discorso_del_Ministro_22_febbraio_2008.pdf
[25]
Bonanni P, Levi M, Latham NB, et al. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin 2011; 7(Suppl.): 128-35.
[http://dx.doi.org/10.4161/hv.7.0.14575] [PMID: 21245659]
[26]
World Health Organization (WHO).; Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines Schedules. Background paper for SAGE discussions March 11 2014; 1-68.Available at:. https://www.who.int/immunization/sage/meetings/ 2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf
[27]
Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine 2018; 36(32 Pt A): 4768-73.
[http://dx.doi.org/10.1016/j.vaccine.2017.12.079] [PMID: 29325819]
[28]
European Medicines Agency (EMA). Gardasil 9. Product information.. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003852/human_med_001863.jsp&mid=WC0b01ac058001d124
[29]
Block SL, Nolan T, Sattler C, et al. Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118(5): 2135-45.
[http://dx.doi.org/10.1542/peds.2006-0461] [PMID: 17079588]
[30]
Einstein MH, Baron M, Levin MJ, et al. HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5(10): 705-19.
[http://dx.doi.org/10.4161/hv.5.10.9518] [PMID: 19684472]
[31]
Zhu FC, Chen W, Hu YM, et al. HPV-039 study group. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer 2014; 135(11): 2612-22.
[http://dx.doi.org/10.1002/ijc.28897] [PMID: 24740596]
[32]
Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Indian HPV Vaccine Study Group. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2016; 17(1): 67-77.
[http://dx.doi.org/10.1016/S1470-2045(15)00414-3] [PMID: 26652797]
[33]
Joura EA, Giuliano AR, Iversen OE, et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372(8): 711-23.
[http://dx.doi.org/10.1056/NEJMoa1405044] [PMID: 25693011]
[34]
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356(19): 1928-43.
[http://dx.doi.org/10.1056/NEJMoa061760] [PMID: 17494926]
[35]
Paavonen J, Naud P, Salmerón J, et al. HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686): 301-14.
[http://dx.doi.org/10.1016/S0140-6736(09)61248-4] [PMID: 19586656]
[36]
Schwarz TF, Huang LM, Lin TY, et al. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J 2014; 33(12): 1255-61.
[http://dx.doi.org/10.1097/INF.0000000000000460] [PMID: 24978856]
[37]
Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018; 5 CD009069
[http://dx.doi.org/10.1002/14651858.CD009069.pub3] [PMID: 29740819]
[38]
Schwarz TF, Huang LM, Valencia A, et al. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Hum Vaccin Immunother 2019; 15(7-8): 1970-9.
[http://dx.doi.org/10.1080/21645515.2019.1625644] [PMID: 31268383]
[39]
Wheeler CM, Castellsagué X, Garland SM, et al. HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13(1): 100-10.
[http://dx.doi.org/10.1016/S1470-2045(11)70287-X] [PMID: 22075170]
[40]
Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15(5): 565-80.
[http://dx.doi.org/10.1016/S1473-3099(14)71073-4] [PMID: 25744474]
[41]
European Medicines Agency (EMA), Gardasil 9. Summary of product characteristics, 2015. Available at:. https:// www.ema.europa.eu/en/documents/productinformation/gardasil-9-epar-product-information_en.pdf
[42]
Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 2017; 390(10108): 2143-59.
[http://dx.doi.org/10.1016/S0140-6736(17)31821-4] [PMID: 28886907]
[43]
Murillo R, Ordóñez-Reyes C. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Int J Gynecol Cancer 2019; 29(8): 1317-26.
[44]
Bogaards JA, van der Weele P, Woestenberg PJ, van Benthem BHB, King AJ. Bivalent human papillomavirus (hpv) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine Types 16 and 18. J Infect Dis 2019; 220(7): 1141-6.
[http://dx.doi.org/10.1093/infdis/jiz280] [PMID: 31165164]
[45]
Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE. High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent hpv infections up to 6 years after vaccination in young dutch women. J Infect Dis 2018; 217(10): 1579-89.
[http://dx.doi.org/10.1093/infdis/jiy067] [PMID: 29409034]
[46]
Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17(12): 1293-302.
[http://dx.doi.org/10.1016/S1473-3099(17)30468-1] [PMID: 28965955]
[47]
Kudo R, Yamaguchi M, Sekine M, et al. Bivalent human papillomavirus vaccine effectiveness in a japanese population: high vaccine-type-specific effectiveness and evidence of cross-protection. J Infect Dis 2019; 219(3): 382-90.
[http://dx.doi.org/10.1093/infdis/jiy516] [PMID: 30299519]
[48]
Latsuzbaia A, Arbyn M, Tapp J, et al. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg. Cancer Epidemiol 2019; 63 101593
[http://dx.doi.org/10.1016/j.canep.2019.101593] [PMID: 31499377]
[49]
Mesher D, Panwar K, Thomas SL, et al. The impact of the national hpv vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016. J Infect Dis 2018; 218(6): 911-21.
[http://dx.doi.org/10.1093/infdis/jiy249] [PMID: 29917082]
[50]
Mollers M, King AJ, Knol MJ, et al. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study. Vaccine 2015; 33(23): 2678-83.
[http://dx.doi.org/10.1016/j.vaccine.2015.04.016] [PMID: 25887090]
[51]
Purriños-Hermida MJ, Santiago-Pérez MI, Treviño M, et al. HPV Vaccine Impact Surveillance Working Group of Galicia. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. PLoS One 2018; 13(8) e0201653
[http://dx.doi.org/10.1371/journal.pone.0201653] [PMID: 30075010]
[52]
Woestenberg PJ, King AJ, van Benthem BHB, et al. Medical Microbiological Laboratories and the Public Health Services. Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among dutch sti clinic visitors. J Infect Dis 2018; 217(2): 213-22.
[http://dx.doi.org/10.1093/infdis/jix582] [PMID: 29140439]
[53]
Woestenberg PJ, King AJ, Van Benthem BHB, et al. Medical Microbiological Laboratories and the Public Health Services. Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the Netherlands. J Infect Dis 2019. In press
[http://dx.doi.org/10.1093/infdis/jiz187] [PMID: 31100134]
[54]
Heard I, Tondeur L, Arowas L, Demazoin M, Falguières M, Parent Du Chatelet I. pour le groupe CHlaHPV. Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France. J Infect Dis 2017; 215(5): 757-63.
[PMID: 28011911]
[55]
Spinner C, Ding L, Bernstein DI, et al. Human papillomavirus vaccine effectiveness and herd protection in young women. Pediatrics 2019; 143(2) e20181902
[http://dx.doi.org/10.1542/peds.2018-1902] [PMID: 30670582]
[56]
Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey, United States, 2003-2014. J Infect Dis 2017; 216(5): 594-603.
[http://dx.doi.org/10.1093/infdis/jix244] [PMID: 28931217]
[57]
Batmunkh T, von Mollendorf C, Tulgaa K, et al. HPV genoprevalence and HPV knowledge in young women in Mongolia, five years following a pilot 4vHPV vaccination campaign. Papillomavirus Res 2019; 8 100175
[http://dx.doi.org/10.1016/j.pvr.2019.100175] [PMID: 31276802]
[58]
Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137(3) e20151968
[http://dx.doi.org/10.1542/peds.2015-1968] [PMID: 26908697]
[59]
Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 2016; 63(4): 519-27.
[60]
Steben M, Tan Thompson M, Rodier C, et al. A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J Obstet Gynaecol Can 2018; 40(12): 1635-45.
[http://dx.doi.org/10.1016/j.jogc.2018.05.024] [PMID: 30341021]
[61]
Drolet M, Bénard É, Pérez N, Brisson M. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394(10197): 497-509.
[http://dx.doi.org/10.1016/S0140-6736(19)30298-3] [PMID: 31255301]
[62]
Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ 2019; 365: l1161.
[http://dx.doi.org/10.1136/bmj.l1161] [PMID: 30944092]
[63]
Lehtinen M, Baussano I, Paavonen J, Vänskä S, Dillner J. Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies. Expert Rev Vaccines 2019; 18(2): 153-60.
[http://dx.doi.org/10.1080/14760584.2019.1568876] [PMID: 30657348]
[64]
Baussano I, Lazzarato F, Ronco G, et al. How human papillomavirus 16 becomes harder to eliminate than other types: a modelling study. J Infect Dis 2017; 216: 366-44.
[65]
Baussano I, Lazzarato F, Ronco G, Franceschi S. Impacts of human papillomavirus vaccination for different populations: a modeling study. Int J Cancer 2018; 143(5): 1086-92.
[http://dx.doi.org/10.1002/ijc.31409] [PMID: 29603224]
[66]
Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 2016; 22(1): 56-64.
[http://dx.doi.org/10.3201/eid2201.150736] [PMID: 26692336]
[67]
Assessorato alle Politiche della salute, Apulia Region, Italy. Atto di programmazione. Intesa Stato Regione del 29 aprile 2010. Piano Regionale della Prevenzione 2010-2012. Approvazione. Deliberazione della Giunta Regionale 28 dicembre 2010, n. 2994. Bollettino Ufficiale della Regione Puglia n 13 del 25-01-2011 Available at:. http://www.regione.puglia.it/www/web/files/sanita/piano%20prevenzione.pdf
[68]
Commissione tecnico-scientifica regionale vaccini, Apulia Region, Italy. Modifica Calendario Regionale per la vita 2012 - DGR 241/2013. Approvazione nuovo Calendario Vaccinale per la vita 2014. Deliberazione della Giunta Regionale 20 maggio 2014, n. 958. Bollettino Ufficiale della Regione Puglia n 74 del 11-06- 2014 19468-86” Available at:. http://www.regione.puglia.it/ index.php?page=burp&opz=getfile&file=N74_11_06_14.pdf
[69]
Ministero della Salute. Aggiornamento della schedula vaccinale anti-papillomavirus e delle modalità di rilevazione delle coperture vaccinali. Circolare 24 aprile 2014 Available at:. http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=1572
[70]
Guido M, Tinelli A, De Donno A, et al. Prevalence and distribution of human papillomavirus genotype in south eastern Italy, in the period 2006-2011: implications for intervention. Curr Pharm Des 2013; 19(8): 1498-507.
[PMID: 23016783]
[71]
Del Prete R, Ronga L, Magrone R, et al. Epidemiological evaluation of human papillomavirus genotypes and their associations in multiple infections. Epidemiol Infect 2019; 147 e132
[http://dx.doi.org/10.1017/S0950268818003539] [PMID: 30869020]
[72]
Coscia MF, Monno R, Ballini A, et al. Human papilloma virus (HPV) genotypes prevalence in a region of South Italy (Apulia). Ann Ist Super Sanita 2015; 51(3): 248-51.
[PMID: 26428051]
[73]
Chen X, Xu H, Xu W, et al. Prevalence and genotype distribution of human papillomavirus in 961,029 screening tests in southeastern China (Zhejiang Province) between 2011 and 2015. Sci Rep 2017; 7(1): 14813.
[http://dx.doi.org/10.1038/s41598-017-13299-y] [PMID: 29093458]
[74]
Dickson EL, Vogel RI, Bliss RL, Downs LS Jr. Multiple-type human papillomavirus (HPV) infections: a cross-sectional analysis of the prevalence of specific types in 309,000 women referred for HPV testing at the time of cervical cytology. Int J Gynecol Cancer 2013; 23(7): 1295-302.
[http://dx.doi.org/10.1097/IGC.0b013e31829e9fb4] [PMID: 23970156]
[75]
Zhang C, Cheng W, Liu Q, Guan Q, Zhang Q. Distribution of human papillomavirus infection: a population-based study of cervical samples from Jiangsu Province. Virol J 2019; 16(1): 67.
[http://dx.doi.org/10.1186/s12985-019-1175-z] [PMID: 31109361]
[76]
Galati L, Peronace C, Fiorillo MT, et al. Six years genotype distribution of Human Papillomavirus in Calabria Region, Southern Italy: a retrospective study. Infect Agent Cancer 2017; 12: 43.
[http://dx.doi.org/10.1186/s13027-017-0154-5] [PMID: 28770002]
[77]
Ronco G, Giorgi-Rossi P, Carozzi F, et al. New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11(3): 249-57.
[http://dx.doi.org/10.1016/S1470-2045(09)70360-2] [PMID: 20089449]
[78]
Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88(1): 63-73.
[http://dx.doi.org/10.1038/sj.bjc.6600688] [PMID: 12556961]
[79]
Ginindza TG, Dlamini X, Almonte M, et al. Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland. PLoS One 2017; 12(1)e0170189
[http://dx.doi.org/10.1371/journal.pone.0170189] [PMID: 28114325]
[80]
Aubin F, Prétet JL, Jacquard AC, et al. EDiTH Study Group. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008; 47(5): 610-5.
[http://dx.doi.org/10.1086/590560] [PMID: 18637758]
[81]
Chan PK, Luk AC, Luk TN, et al. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol 2009; 44(2): 111-4.
[http://dx.doi.org/10.1016/j.jcv.2008.11.001] [PMID: 19097933]
[82]
Tiggelaar SM, Lin MJ, Viscidi RP, Ji J, Smith JS. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health 2012; 50(2): 110-31.
[http://dx.doi.org/10.1016/j.jadohealth.2011.10.01] [PMID: 22265107]

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy